Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

Publisher： Karger

E-ISSN： 1664-5502|7|3|188-197

ISSN： 1664-3828

Source： Cardiorenal Medicine, Vol.7, Iss.3, 2017-04, pp. : 188-197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

By  

American Journal of Nephrology, Vol. 45, Iss. 3, 2017-02 ,pp. : 235-247

Karger

Access to resources Recommend Favorite

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-11 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Possible Inhibitory Effect of Erythropoiesis-Stimulating Agents at the Predialysis Stage on Early-Phase Coronary Events after Hemodialysis Initiation

By  

Cardiorenal Medicine, Vol. 7, Iss. 1, 2016-08 ,pp. : 21-30

Karger

Access to resources Recommend Favorite

Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients

By  

Nephron, Vol. 131, Iss. 2, 2015-0 ,pp. : 123-130

Karger

Access to resources Recommend Favorite

Healthcare Resource Utilization for Anemia Management: Current Practice with Erythropoiesis-Stimulating Agents and the Impact of Converting to Once-Monthly C.E.R.A.

By  

Blood Purification, Vol. 26, Iss. 6, 2008-11 ,pp. : 537-546

Karger

Access to resources Recommend Favorite